All In MedTech

Device Trial Radar · NCT05305534

QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study

Clinical Performance Evaluation Study of the QIAstat-Dx® BCID GN and GPF Plus AMR Panels on Positive Blood Culture and Pure Colony Isolates From Subjects With Signs and Symptoms of Bloodstream Infection

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,142

Actual

Start

Dec 1, 2023

Primary completion

Apr 10, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
QIAGEN Gaithersburg, IncNot on our public-company list
Sponsor type
Industry
First posted
Mar 31, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods

Conditions

  • Blood Disease

Interventions

  • QIAstat-Dx® BCID GN and GPF Plus AMR PanelsDevice

    The performance of QIAstat-Dx® BCID GN and GPF Plus AMR Panels will be evaluated in comparison with another validated comparator method, using residual specimens of positive blood culture. Pure colonies derived from the residual positive blood culture specimens will also be tested

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PPATime frame: 6 moths

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QIAGEN

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.